KeyBanc upgrades CryoPort stock rating to Overweight on CGT momentum

Investing.com - KeyBanc upgraded CryoPort (NASDAQ:CYRX) from Sector Weight to Overweight on Wednesday, setting a price target of $15.00 following the company’s strong second-quarter performance. Currently trading at $6.74, InvestingPro data shows the stock has experienced a -10.6% decline over the past week, though analysts maintain an overall bullish consensus with targets ranging from $6.50 to $15.00.

The upgrade comes after CryoPort reported better-than-expected second-quarter 2025 results, with 33% revenue growth in commercial cell and gene therapies, 28% growth in its BioStorage business, and 21% growth in Life Sciences Services. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 5.56, while operating with a moderate debt level.

KeyBanc noted that commercial therapies now represent approximately 20% of CryoPort’s quarterly revenue, up from 10% a year ago, and are projected to grow at a 31.5% compound annual growth rate through 2030.

The firm highlighted CryoPort’s recent divestiture of CRYOPDP to DHL for $196 million, which closed in the second quarter of 2025, as a strategic move that positions the company within DHL’s extensive network while strengthening its balance sheet.

CryoPort’s cost initiatives and volume leverage have improved its adjusted EBITDA margin to ($0.9 million) in the quarter compared to ($3.8 million) in the same period last year, according to KeyBanc’s analysis.

In other recent news, Cryoport Inc . reported its second-quarter 2025 earnings with a notable revenue performance that exceeded expectations. The company achieved earnings per share of $2.05, significantly surpassing the forecasted -$0.27, indicating a major surprise for analysts and investors alike. Revenue figures reached $45.5 million, which was 9.01% higher than the anticipated $41.74 million. Despite these positive financial results, Cryoport’s stock experienced a decline in aftermarket trading. The company’s stock fell by 6.01%, closing at $7.16. These developments indicate a complex market response to Cryoport’s financial report, highlighting the importance of earnings and revenue figures in investor decision-making.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.